FABP5 and early-onset autosomal dominant Alzheimer disease: Multiple studies have reported that aberrant expression of Fabp5 under pathological conditions is associated with various diseases, including metabolic disorders [42], psoriasis [43], Alzheimer's disease [44], and malignant tumors [45], indicating its potential for clinical applications.